PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Clinical trials for PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL) explained in plain language.
Never miss a new study
Get alerted when new PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL) trials appear
Sign up with your email to follow new studies for PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New dosing schedule of immunotherapy shows promise for hard-to-treat lymphomas
Disease control CompletedThis study tested the drug pembrolizumab (Keytruda) given every 6 weeks to 66 adults whose Hodgkin lymphoma or primary mediastinal large B-cell lymphoma had come back or not responded to prior treatment. The main goal was to see how many patients had their tumors shrink or disapp…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
633 PMBCL patients studied: key insights on refractory disease and survival
Knowledge-focused CompletedThis study looked back at 633 people with primary mediastinal large B-cell lymphoma (PMBCL) treated in Italy between 2007 and 2019. Researchers collected data on how well treatments worked, how many patients had disease that didn't respond or came back early, and survival rates. …
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC